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Abstract
An in vitro model that can be realistically and inexpensively used to predict human response to 
various drug administration and toxic chemical exposure is needed. By fabricating a microscale 
3D physiological tissue construct consisting of an array of channels and tissue-embedded 
chambers, one can selectively develop various biomimicking mammalian tissues for a number of 
pharmaceutical applications, for example, experimental pharmaceutical screening for drug 
efficacy and toxicity along with apprehending the disposition and metabolic profile of a 
candidate drug. This paper addresses issues relating to the development and implementation of a 
bioprinting process for freeform fabrication of a 3D cell-encapsulated hydrogel-based tissue 
construct, the direct integration onto a microfluidic device for pharmacokinetic study, and the 
underlying engineering science for the fabrication of a 3D microscale tissue chamber as well as 
its application in pharmacokinetic study. To this end, a prototype 3D microfluidic tissue chamber 
embedded with liver cells encapsulated within a hydrogel matrix construct is bioprinted as a 
physiological in vitro model for pharmacokinetic study. The developed fabrication processes are 
further validated and parameters optimized by assessing cell viability and liver cell phenotype, in 
which metabolic and synthetic liver functions are quantitated. 
1. Introduction 
Tissue engineering approaches exploit living cells in a variety of ways towards the goal of 
restoring, maintaining, or enhancing tissues and organs [1,2]. In order to engineer biological 
tissues in vitro, cultured cells are coaxed to grow on bioactive resorbable scaffolds, i.e. 
temporary synthetic extracellular matrices that provide the biological, chemical, and mechanical 
cues to guide the cell’s eventual differentiation and assembly into three-dimensional (3D) tissues 
[3]. While regeneration of different tissues and organs are currently under heavy investigation 
and development, new applications of tissue engineering in designing in vitro physiological 
models to study disease pathogenesis and for pharmacokinetic study are also extremely 
promising [4]. One possible application of in vitro physiological models established from 
biology-based engineering analysis is in the area of pharmaceutical drug screening and new drug 
discovery and development. In vitro cell culture models with human liver cells have already 
shown great potential in predicting studies on drug toxicity and metabolism in the 
pharmaceutical industry [5,6].  For example, Zeilinger et al developed a bioreactor culture model 
that permits the 3D coculture of liver cells under continuous medium perfusion with 
decentralized mass exchange and integral oxygenation [7]. Powers and Domansky designed a 
microfabricated array bioreactor for perfused 3D liver culture at reported perfusate flow rates 
and fluid shear stresess at or below the physiological shear range in vivo. These primary rat liver 
cells cultured for two weeks in the channels rearranged themselves to form tissue-like structures. 
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Shuler et al has conceived a microscale in vitro system to serve as a human surrogate for drug 
analysis which adheres stringently to a physiologically-based pharmokinetic (PBPK) model in 
which disparate organs are serially connected by channels to comprise a fluid circuit. This 
methodology is then used to mechanistically simulate and predict the fate of drugs or other 
substances in vivo. Therefore, one can conceive and fabricate a stamp-sized animal-on-a-chip 
microfluidic device which, with great fidelity, replicates an experimental drug’s being broken 
down by the metabolizing liver, absorbed by the intestines, and held onto by fat [8-10].
The present work explores the development and study of in vitro three-dimensional 
Microfluidic Microanalytical Microorgan Device (3MD) for simulation of physiological human 
response to drug administrations and toxic chemical exposure.  The applied solid freeform 
fabrication technology is a viable bioprinting freeform fabrication process for layer-by-layer 
extrusion of 3D cell-encapsulated hydrogel-based tissue constructs. By fabricating a 3D in vitro
tissue analog consisting of an array of channels with tissue-embedded chambers, one can 
selectively biomimic different mammalian tissues for a multitude of applications, foremost 
among them liver tissue for clinical pharmaceutical screening of drug efficacy and toxicity.  The 
research conducted is aimed at the achievement of high-throughput reproducible fabrication of 
bioprinted tissue constructs and 3D organ chambers, maintenance of structural integrity and the 
integration with the microfluic platform, and enhancement of cell viability and cell phenotype 
retention. More specifically, the objectives are to develop a viable bioprinting process for 
fabrication of reproducible 3D cell-encapsulated alginate-based tissue constructs; to fabricate 3D 
organ chambers, i.e., bioprinted liver tissue constructs with surface-treated silicon microfluidic 
devices; and to study the effect of the process on cell viability and cell-specific function retention. 
2. System Configuration for 3D Tissue Constructs Within Microfluidic Device 
2.1 Overview
The bioprinting process is integrated with a microfluidic device to fabricate 3D tissue/organ 
constructs/chambers, as opposed to producing 2D cell monolayers (Figure 1). Biological studies 
reveal the instability cellular phenotype and reduced tissue-specific gene expression with 
conventional monolayer in vitro culture techniques [11-13]. A three-dimensional tissue model 
will, in contrast, foster improved retention of hepatocyte-specific function.   
Figure 1:  Overview of Bioprinting Tissue-on-a-Chip Approach 
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Furthermore, direct cell deposition of encapsulated cells offers tighter control over the spatial 
distribution of cells and doesn’t rely upon cell migration to populate the scaffold, allowing one to 
assembly high cell density or co-culture multiple cell types within a 3-dimensional construct. 
This can create tissue structures that more closely resemble their in vivo state. Cell-cell 
communication either from direct contact or paracrine signaling is important for proper cellular 
behavior, differentiation, and proliferation, along with the concomitant extracellular matrix 
produced by the neighboring cells.  Furthermore, optimization of process parameters (e.g. nozzle 
pressure, motion arm velocity, nozzle tip size etc.) and material parameters (e.g. biopolymer 
viscosity, crosslinking agent concentrations, etc.) have been done to achieve high-fidelity 3D 
structures and seamless integration onto a microfluidic tissue micro-organ chambers. 
2.2 Modifications of System for Tissue-on-a-chip Application
First, mouse hepatocytes are encapsulated within alginate hydrogels and bioprinted through 
the system into a desired pattern within the microfluidic circuits. The other component to the 
microfluidic microanalytical microorgan device (3DM) system is the micofluidic device with 
indented chambers. The feasibility of using a standard soft-lithography technique is explored to 
fabricate microscale in vitro device with microchannels and multi-chambers to house the 
bioprinted tissue. The preferred material for fabrication of the microchip for housing the 
embedded tissue is PDMS. PDMS elastomer soft lithography is combined with the micro-
molding techniques to fabricate 3D micro-fluidic chambers. The advantages of these fabricated 
chambers are the ease of bonding, optical properties, and permeability to gases for biological 
application.
Figure 2:  Setup of Bioprinted Tissue-on-a-chip for Medium/Drug Flow Study 
The next step is to bioprint the the cell-encapsulated alginate constructs within a PDMS 
chambers. The PDMS chambers contain a 10mm x 10mm x 0.6mm (Width x Length x Height) 
indentation.  In order to integrate the hydrophilic alginate constructs onto the PDMS substrate, 
UV treatment was applied to the PDMS chips to oxidize the surface methyl groups to form 
silanol groups along with roughening the surface.  Therefore, a hydrophilic surface with good 
wettability and improved traction is attained.  Next, the cell-encapsulated alginate construct is 
directly bioprinted within the tissue chamber indentation on the PDMS microchip, thus forming 
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an integrated 3-D tissue chamber unit.  Figure 2 shows a setup of applying such tissue-on-a-chip 
unit for medium/drug flow study.  
A schematic of medium/drug flow circulation in the mini-bioreactor is shown in Figure 3. To 
demonstrate effective drug metabolism in the liver chamber, a non-fluorescent prodrug is fed 
into the system through the inlet port, metabolized by the liver chamber, and then produces an 
effluent fluorescent metabolite for analysis collected at the outlet port. Results of such analysis 
can be used to understand the relative pharmacokinetic efficiency as well as relevancy of the 
tissue chambers design for human application.   
Figure 3:  Schematic of Medium/Drug Flow Circuit through tissue chambers 
3. Bioprinting on a Chip Pattern 
3.1 Overview of existing bioprinting system
A proprietarily developed Drexel multinozzle bioprinting system is capable of depositing 
heterogeneous materials, cell types, and biological factors in a controlled and reproducible 
manner [14,15]. This bioprinting process employs solid freeform fabrication (SFF) techniques in 
conjunction with computer-aided modeling of heterogeneous structures to build biopolymer-
based 3D cell-embedded tissue constructs. The deposition system utilizes microvalve nozzle 
systems that can deposit a wide range of solutions with a wide range of material and biological 
properties. The system configuration allows a pre-specified computer-aided design (CAD) to be 
converted into a layered process toolpath to extrude biopolymeric materials, cells, and other 
biological factors through various nozzle systems. An overview of the bioprinting system 
configuration is shown in Figure 4.
3.2 Fluid dynamical modeling of the bioprinting system
The bioactive fabrication process described herein involves extruding live cells admixed 
homogeneously with sodium alginate through the pneumatic system. In the deposition, the cells 
are exposed to the shear mechanical perturbations within the cell suspension that could 
potentially permanently kill or temporarily damage cells, thereby altering functionality (e.g., 
drug metabolism). Therefore, an expression for the shear stress would be helpful in quantifying 
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the amount of shear that cells may experience as they traverse the pneumatic-driven bioprinting 
nozzle system. 
Figure 4:  Overview of System Configuration of 3D Bioprinting System 
Fundamental equations from fluid dynamics can be integrated into an analytical model of the 
mechanical forces on cells and biomaterial flowing through a nozzle tip.  First of all, for flow 
within a specified nozzle tip, the pressure gradient in the z direction (direction of deposition) can 
be expressed as: 
1 ( )    rzdp d r g
dz r dr
? ?? ? ?                                            (1)
where ?rz is the shear stress and ? is density of cell suspension. 
Hence,
1 ( )   =    out inrz p pd r g
r dr L
? ? ??                                    (2) 
Where L is the length of the nozzle tip and pin, pout are pressures at nozzle entry and exit 
respectively. 
Upon integration, Eq (2) becomes: 
( )   
2
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rz
p gL p r C
L r
?? ? ?? ?           (3) 
Applying boundary conditions where ?rz must be finite at r=0, constant C becomes 0, and 
therefore the expression for shear stress as a function of radius is: 
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Further, the maximum shear stress ?max in the pneumatic nozzle is represented in terms of the 
process parameters as shown in Equations (3.59) and (3.60): 
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where ? is the viscosity, 
.
? is the shear rate, R is the nozzle tip radius, constant K is the 
consistency index, and the constant n is the power law index that is equal to unity for Newtonian 
liquids and is less than one for non-Newtonian liquids [16].
3.3 Bioprinted 3D Tissue Construct Structural Formability 
A micro-scale liver tissue analog has been designed and fabricated for studying drug 
metabolism and its pharmacokinetic effects on secondary organ function via direct deposition of 
a three dimensional heterogeneous cell-seeded hydrogel-based matrix. By integrating the 
bioprinting system with a CAD environment, notable feasibility and reproducibility of 3D 
structures has been realized within micron-order dimensional specifications and hence can be 
used for parametric studies (Figure 5).  
      
Figure 5:  Bioprinted Tissue Construct Structural Formability 
4. Preliminary Study of Cell Viability and Hepatocyte-Specific Function
4.1 Preliminary Study of Cell Viability
Preliminary cell viability assays were conducted to study the effect of the bioprinting process 
on cell survival.  The aim of this study was to evaluate the cell viability ratio at Day 0 of the 
bioprinting system.  The experimental setup for this study (Figure 6) involved 2 test samples and 
one control.  Test 1 was the bioprinting of alginate and hepatocytes with cell medium serving as 
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the cross-linking agent.  Test 2 was the bioprinting of alginate and hepatocytes with a CaCl2
polymerizing cross-linker.  Both the process and material parameters for Test 1 and Test 2 were 
held constant.  The control implemented was manual pipetting of alginate and hepatocytes with 
cell medium as the cross-linking agent.  The same cell density (175,000 cells/mL) was used in 
both tests and the control.
Figure 6:  Post-Processing Hepatocyte Cell Viability 
For this setup, qualitative and quantitative assays were carried out with Live/Dead cell assay and 
Alamar Blue cell assay respectively.  Each data point represented samples taken at Day 0 shortly 
after bioprinting and subsequent cross-linking.  The rationale for this setup with assay was to 
compare and isolate the effects of the bioprinting process and biomaterial cross-linking agent on 
the cell viability.  Preliminary testing demonstrated good initial cell viability of post-assembly 
bioprinted encapsulated hepatocytes under biofriendly conditions with Live/Dead cell assays and 
Alamar Blue staining (Figure 8).   
(a) Live-Dead Cell Assay (b) Alamar Blue Quantitative Cell Viability Assay 
Figure 7:  Post-Processing Hepatocyte Cell Viability 
Figure 7a is a qualitative assessment at Day 0 of the cell viability with metabolically live 
cells denoted in green and metabolically inactive dead cells in red.  Figure 7b shows the cell 
viability ratios at Day 0 obtained from quantitative fluorescent measurements of the two test 
setups and control.  The control with no bioprinting and cell medium cross-linker showed 83% 
cell viability.  Test 1 bioprinting alginate/hepatocytes with cell medium cross-linker 
Hepatocyte Cell Viability as a Function of Process 
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demonstrated a 79% cell viability.  Test 2 bioprinting alginate/hepatocytes with CaCl2 cross-
linker gave a 70% cell viability.  A comparison of Test 1 and control indicated a slight drop in 
cell viability may be attributed to the bioprinting process.  Further, a comparison of Test 2 and 
Test 1 indicated that a larger drop in cell viability may be attributed to the substitution of a 
stronger cross-linker (CaCl2) versus one with trace amounts of cross-linking ions (cell medium).  
Overall, the cell viability tests showed that hepatocytes were able to survive through bioprinting 
process with a range of 70% to 79% viability ratio depending on choice of chemical cross-
linking agent. 
4.2 Preliminary Result of Urea Synthesis for Hepatocyte Function
A 3-day preliminary study was performed to investigate differential hepatocyte-specific 
function of urea synthesis in bioprinted 3D alginate encapsulated hepatocytes and 2D hepatocyte 
cell monolayer.  The aim of this study was to evaluate the implications of a bioprinted 3D 
structure on a measure of hepatocyte-specific function, namely urea synthesis.  The experimental 
setup for this study involved one experimental test sample and one control. The experimental test 
sample was the bioprinting of a 3D hepatocyte/alginate tissue construct.  The control used was a 
2D hepatocellular monolayer with the same cell density (175,000 cells/mL) as the test sample.  
In Figure 8, urea synthesis is quantitatively detected with a cell-based colorimetric assay, 
allowing comparison of time-dependent phenotype for bioprinted cell-encapsulated hepatocytes 
with controls cultured as a hepatocellular monolayer.  Cell medium was replenished for both the 
test sample and control once per day.  Each data point was an average of 5 samples taken at Days 
1, 2, and 3 after bioprinting. 
Figure 8: Results of 3-day Urea Synthesis Study of Bioprinted Alginate
Tissue Constructs of Microencapsulated Hepatocytes 
This data suggests that a hepatocytes encapsulated in a 3D alginate/hepatocyte tissue contruct 
synthesizes a higher amount of urea than the same number of hepatocytes cultured as a 2D 
hepatocyte cell monolayer. This difference wass most striking on Day 1, where the 3D tissue 
construct showed a marked urea concentration of 1.90mg/mL compared to a 2D hepatocyte cell 
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monolayer urea concentration of 0.65mg/mL.  While the marked dropoff in urea synthesis at Day 
3 was typical of in vitro culture, the 3D structure conferred an ability for increased urea 
production relative to the 2D monolayer case.  Therefore, this demonstrated that the bioprinting 
process for microencapsulation of hepatocytes in 3D alginate tissue constructs was compatible 
with prolonged maintenance of hepatotocellular specific function.
5.   Discussion and Conclusions 
Over the last four years, the development of integrated devices that combine cell culture and 
microfabrication makes the possibility of commercial applications to pharmaceutical evaluation a 
real possibility. The research undertaken herein rests on the premise and conviction that an in 
vitro model that can realistically and inexpensively test the response of humans and animals to 
various chemicals is needed. Such an in vitro system may serve to improve our ability to predict 
animal and human response to drug and chemical exposure. Process development of a 
proprietary bioprinting system to fabricate tissue construct for direct integration on a 
microfluidic chip will enable a novel creation of a tissue analog for pharmacokinetic study.  
Bioprinting tissue constructs with 3D architecture and microscale design features has been 
demonstrated for both feasibility and reproducibility. Cell viability tests showed that hepatocytes 
were able to survive through bioprinting process with a range of 70% to 79% viability ratio.  
Furthermore, biological assays for liver-specific function showed a conferred advantage of a 3D 
tissue construct over 2D cell monolayer for maintenance of cell-specific function.  Ongoing 
research and study are being done to enhance feasibility of bioprinted 3-dimensional structural 
formation with reproducibility, integration of bioprinted tissue onto a microfluidic device with 
no leakage, cell viability, and maintenance of cell-specific function.  By taking advantage of the 
unique bioprinting system capabilities, advanced research topics can be pursued in tissue 
engineering and its downstream applications, specifically pharmacokinetic study for drug 
screening and development. The potential impact of the tissue-engineered model physiological 
surrogate system developed herein will hinge on a deepened appreciation of the engineering and 
scientific basis for the fabrication as well as the relation with subsequent tissue pharmacokinetic 
behavior
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